周盈,黃倩,王帥,陳萍
(1.浙江大學(xué)農(nóng)業(yè)與生物技術(shù)學(xué)院茶學(xué)系,杭州310058;2.浙江大學(xué)基礎(chǔ)醫(yī)學(xué)院,杭州310058)
茶黃素對(duì)白介素-1β誘導(dǎo)的大鼠軟骨細(xì)胞炎性退變的影響
周盈1?,黃倩2?,王帥2,陳萍1*1
(1.浙江大學(xué)農(nóng)業(yè)與生物技術(shù)學(xué)院茶學(xué)系,杭州310058;2.浙江大學(xué)基礎(chǔ)醫(yī)學(xué)院,杭州310058)
采用白介素-1β(interleukin-1β,IL-1β)對(duì)體外培養(yǎng)的正常大鼠軟骨細(xì)胞進(jìn)行誘導(dǎo),構(gòu)建骨關(guān)節(jié)炎(osteoarthritis,OA)炎性退變細(xì)胞模型,探討茶黃素(theaflavins,TFs)治療骨關(guān)節(jié)炎的可行性。通過(guò)甲苯胺藍(lán)及免疫熒光染色對(duì)細(xì)胞進(jìn)行鑒定,利用CCK-8細(xì)胞活力檢測(cè)篩選TFs藥物濃度;取第2代生長(zhǎng)狀況良好的大鼠膝關(guān)節(jié)軟骨細(xì)胞,根據(jù)所加培養(yǎng)物的不同將實(shí)驗(yàn)分為3組:空白組G0、模型組G1(10 ng/mL IL-1β刺激)、TFs組G2(不同濃度的TFs+10 ng/mL IL-1β刺激),通過(guò)實(shí)時(shí)熒光定量聚合酶鏈?zhǔn)椒磻?yīng)(quantitative real-time polymerase chain reaction, qRT-PCR)檢測(cè)各組Ⅱ型膠原(typeⅡcollagen,ColⅡ)、蛋白聚糖(aggrecan,ACAN)、基質(zhì)金屬蛋白酶-13(matrix metalloproteinases-13,MMP-13)、IL-1β及環(huán)氧合酶-2(cyclooxygenase-2,COX-2)mRNA的表達(dá)。結(jié)果表明,甲苯胺藍(lán)及免疫熒光染色結(jié)果呈陽(yáng)性,證實(shí)體外分離培養(yǎng)的細(xì)胞為軟骨細(xì)胞。CCK-8檢測(cè)結(jié)果顯示:TFs質(zhì)量濃度在100 μg/mL時(shí),細(xì)胞活力較空白組明顯減弱(P<0.05);TFs質(zhì)量濃度在0~75 μg/mL時(shí)不影響軟骨細(xì)胞活力。qRT-PCR結(jié)果表明:與空白組相比,模型組中合成因子ColⅡ和ACAN mRNA表達(dá)量極顯著降低(P<0.01),分解因子MMP-13、炎癥細(xì)胞因子IL-1β及炎癥誘導(dǎo)酶COX-2 mRNA表達(dá)量極顯著增加(P<0.01);與模型組相比,TFs組能抑制IL-1β引起的炎癥相關(guān)因子mRNA的表達(dá),且呈濃度依賴性(P<0.05)。綜上所述,茶黃素可通過(guò)增強(qiáng)軟骨細(xì)胞合成因子活性、減弱分解因子活性并抑制細(xì)胞炎癥反應(yīng),有效延緩大鼠軟骨細(xì)胞炎性退變進(jìn)程,對(duì)炎癥軟骨細(xì)胞有一定的保護(hù)作用。
茶黃素;骨關(guān)節(jié)炎;軟骨細(xì)胞;白介素-1β;環(huán)氧合酶-2;炎性退變
Summary Osteoarthritis(OA)is a degenerative joint disease with an obviously increasing morbidity as age increases,which seriously affects old people’s joint function and life quality.The key to pathological changes in OA is the damage and loss of articular cartilage.Inflammatory cytokines,such as interleukin-1β(IL-1β),could induce cartilage degeneration and inflammatory reaction through a series of cascade reactions,especially in cartilage lesions.Theaflavins(TFs)are the main active ingredients of black tea polyphenols with anti-inflammation and antioxidant functions.This study focuses on the protective effects of TFsagainst inflammatory degeneration of rat chondrocytes and evaluates the feasibility of TFs in the treatment of OA.
Male Sprague-Dawley rat’s knee articular chondrocytes were isolated and cultured in vitro,which were identified by toluidine blue staining and typeⅡcollagen immunofluorescence staining.To select the concentration levels of TFs,cell viability was analyzed with a cell counting kit-8(CCK-8)assay.Three groups were set in this experiment according to different cultures: blank control group G0,model group G1(10 ng/mL IL-1β)and TFs group G2(different concentrations of TFs+10 ng/mL IL-1β). The changes in the mRNA expression levels of two anabolic factors ColⅡ(typeⅡcollagen)and ACAN(aggrecan),the main catabolic factors MMP-13(matrix metalloproteinases-13),IL-1β,and COX-2(cyclooxygenase-2)in rat chondrocytes were detected by quantitative real-time polymerase chain reaction(qRT-PCR).
It can be found from the inverted phase contrast microscopy that IL-1β obviously impaired normal rat chondrocyte morphology.It can be seen from the fluorescent microscope that the cell nucleus was stained to be blue and cytoplasm was stained to be green by typeⅡcollagen immunofluorescence staining,and the extracellular matrix of cells was stained to be blue-purple by toluidine blue staining,which means the cultured cells in the experiment are chondrocytes.The CCK-8 assay indicated that 100 μg/mL TFs significantly decreased the cell viability of normal rat chondrocytes(P<0.05),but 0-75 μg/mL TFs had no significant cytotoxicity to chondrocytes.The results of qRT-PCR showed that compared with the control group,the mRNA expression levels of chondrocyte markers(ColⅡand ACAN)were obviously down-regulated in the model group(P<0.01),and the mRNA expression levels of MMP-13,IL-1β and COX-2 increased obviously in the model group(P<0.05).For the changes,however,the gene expressions of these inflammatory related factors were significantly inhibited by TFs in a dose-dependent manner compared with the model group(P<0.05).
In conclusion,TFs could effectively alleviate the inflammatory degeneration of rat chondrocytes,via up-regulating anabolic activity,down-regulating catabolic activity and inhibiting inflammatory reaction,so as to protect rat chondrocyts from OA induced by IL-1β.This study provides the first evidence that TFs can significantly inhibit OA disease progression and exert a palliative effect.
骨關(guān)節(jié)炎(osteoarthritis,OA)是一種常見(jiàn)的慢性關(guān)節(jié)疾病,主要是由關(guān)節(jié)磨損退化而引起的關(guān)節(jié)軟骨退行性變和繼發(fā)性骨質(zhì)增生[1]。據(jù)世界衛(wèi)生組織統(tǒng)計(jì),OA多見(jiàn)于65歲以上人群,發(fā)病率高達(dá)80%,臨床表現(xiàn)為關(guān)節(jié)疼痛、僵硬、腫脹、活動(dòng)受限甚至畸形等,是老年人關(guān)節(jié)疼痛和致殘的主要原因[2-3]。軟骨細(xì)胞是關(guān)節(jié)軟骨中唯一的細(xì)胞,在軟骨形成、代謝修復(fù)中起著重要的作用。骨關(guān)節(jié)炎最重要的病理變化是軟骨退變。相關(guān)研究報(bào)道表明,驅(qū)動(dòng)關(guān)節(jié)軟骨退變進(jìn)程的主要因素是慢性炎癥及關(guān)節(jié)軟骨細(xì)胞外基質(zhì)(extracellular matrix,ECM)的降解[4]。炎癥細(xì)胞因子通過(guò)改變軟骨細(xì)胞微環(huán)境,引起ECM合成和分解代謝失衡,致使關(guān)節(jié)軟骨退變,進(jìn)而促進(jìn)OA發(fā)展進(jìn)程[5-6]。大量研究證實(shí),白介素-1β(interleukin-1β,IL-1β)在OA軟骨基質(zhì)合成分解代謝中起到關(guān)鍵作用,可通過(guò)促進(jìn)ECM基質(zhì)降解[7],刺激軟骨細(xì)胞分泌更多的促炎因子和炎癥介質(zhì)[8],進(jìn)一步干擾細(xì)胞功能,在細(xì)胞與細(xì)胞外基質(zhì)之間形成一種正反饋通路,促進(jìn)OA發(fā)展。
茶葉起源于我國(guó),至今已有近3 000年歷史,其藥用價(jià)值也早有記載。茶黃素(theaflavins,TFs)是紅茶中決定色香味及品質(zhì)的主要功能成分,是一種極具開(kāi)發(fā)潛力的藥物資源。TFs屬于紅茶多酚,主要由兒茶素和沒(méi)食子酸等酚類物質(zhì)氧化形成,其主要的單體有4種:茶黃素、茶黃素-3-沒(méi)食子酸酯、茶黃素-3′-沒(méi)食子酸酯及茶黃素雙沒(méi)食子酸酯,分子結(jié)構(gòu)如圖1所示。近年來(lái),TFs抗炎生理活性研究受到廣泛關(guān)注,現(xiàn)已證實(shí)其在肝炎[9]、類風(fēng)濕性關(guān)節(jié)炎[10]、肺炎[11]及慢性疾病[12]中表現(xiàn)出一定的抗炎活性。但關(guān)于TFs在骨關(guān)節(jié)炎癥中的抗炎活性及機(jī)制研究尚未見(jiàn)報(bào)道。由于OA疾病產(chǎn)生的原因包括促炎因子引起的軟骨細(xì)胞功能障礙及其產(chǎn)生的炎癥反應(yīng)[13],因此,探究TFs的抗炎機(jī)制可為防治骨關(guān)節(jié)炎疾病提供一定的理論基礎(chǔ)。本實(shí)驗(yàn)采用IL-1β誘導(dǎo)體外培養(yǎng)的正常大鼠軟骨細(xì)胞,構(gòu)建OA炎性退變細(xì)胞模型,首次研究茶黃素在軟骨細(xì)胞合成及分解代謝中對(duì)ECM穩(wěn)態(tài)的保護(hù)作用及抗炎功效,為其對(duì)骨關(guān)節(jié)炎防治作用的研究提供理論參考。
圖14 種主要茶黃素單體的化學(xué)結(jié)構(gòu)式Fig.1Chemical structures of four theaflavin monomers
1.1 材料與試劑
茶黃素,來(lái)源于紅茶提取物,純度80%,貨號(hào)T5550,購(gòu)自美國(guó)Sigma公司;重組大鼠IL-1β購(gòu)自英國(guó)Peprotech公司;胎牛血清(fetal bovine serum,FBS)、雙抗溶液(青霉素/鏈霉素)、磷酸鹽緩沖液(phosphate buffer saline,PBS)和DEME/F 12培養(yǎng)液均購(gòu)自美國(guó)Gibco公司;CCK-8試劑盒購(gòu)自日本同仁化學(xué)研究所;抗熒光淬滅封片液和4',6-二脒基-2-苯基吲哚(4',6-diamidino-2-phenylindole,DAPI)細(xì)胞染色液均購(gòu)自上海碧云天公司;Ⅱ型膠原(typeⅡcollagen, ColⅡ)抗體購(gòu)自美國(guó)Santa Cruz公司;基質(zhì)金屬蛋白酶-13(matrix metalloproteinases-13,MMP-13)抗體、β-actin抗體、辣根過(guò)氧化物酶標(biāo)記的抗兔和抗小鼠IgG抗體均購(gòu)自美國(guó)CST公司;山羊抗兔Dylight 488熒光二抗購(gòu)自美國(guó)Abcam公司;Trizol試劑購(gòu)自美國(guó)Invitrogen公司;SYBR?Green Supermix試劑盒購(gòu)自美國(guó)Bio-Rad公司;ReverTra Ace?購(gòu)自日本ToYoBo公司;熒光定量聚合酶鏈?zhǔn)椒磻?yīng)引物購(gòu)自上海生物工程技術(shù)有限公司。
實(shí)驗(yàn)動(dòng)物采用清潔級(jí)雄性SD(Sprague-Dawley)大鼠,體質(zhì)量120~150 g,來(lái)源于浙江省實(shí)驗(yàn)動(dòng)物中心。所有動(dòng)物實(shí)驗(yàn)的操作均經(jīng)過(guò)浙江大學(xué)動(dòng)物中心倫理委員會(huì)批準(zhǔn)。
1.2 儀器與設(shè)備
JB-CJ-1FX超凈工作臺(tái)(蘇州佳寶凈化工程設(shè)備有限公司);Galaxy系列二氧化碳培養(yǎng)箱(英國(guó)RS Biotech公司);Nikon倒置相差顯微鏡(日本Nikon公司);Western blot電泳轉(zhuǎn)膜裝置(美國(guó)Bio-Rad公司);NanoDrop蛋白核酸定量?jī)x(美國(guó)NanoDrop公司);480Ⅱ熒光定量PCR儀(美國(guó)Roche公司);G:BOX化學(xué)發(fā)光成像儀(英國(guó)Syngene公司)。
1.3 方法
1.3.1 軟骨細(xì)胞分離、培養(yǎng)及傳代
用6 mg/mL戊巴比妥鈉對(duì)SD大鼠麻醉致死后,將其浸泡于75%乙醇10 min。在無(wú)菌條件下打開(kāi)膝關(guān)節(jié),分離關(guān)節(jié)軟骨面,轉(zhuǎn)移至超凈工作臺(tái),用滅菌手術(shù)刀削下軟骨碎片,剪碎轉(zhuǎn)移至含有2 mL 0.2%膠原酶的6 cm培養(yǎng)皿中消化;30 min后,在原6 cm培養(yǎng)皿中補(bǔ)加3 mL完全培養(yǎng)基(含10%FBS及1%青、鏈霉素),轉(zhuǎn)移至37℃、5%CO2培養(yǎng)箱中進(jìn)行常規(guī)培養(yǎng);24 h后,將組織懸液轉(zhuǎn)移至15 mL離心管內(nèi),1.2萬(wàn)r/min離心5 min后棄上清液,用完全培養(yǎng)基將細(xì)胞吹打均勻,接種至原培養(yǎng)皿中培養(yǎng)。待細(xì)胞貼壁長(zhǎng)滿至80%~90%后進(jìn)行傳代,期間每隔2 d進(jìn)行細(xì)胞換液,于倒置相差顯微鏡下觀察細(xì)胞生長(zhǎng)狀況。
1.3.2 甲苯胺藍(lán)染色鑒定軟骨細(xì)胞
取大鼠第1代軟骨細(xì)胞,胰酶消化后以2×104個(gè)/孔細(xì)胞密度接種到鋪有多聚賴氨酸蓋玻片的24孔板中,置于培養(yǎng)箱中常規(guī)培養(yǎng)細(xì)胞爬片24 h。取出制備好的第2代細(xì)胞爬片,用95%乙醇固定20 min,PBS漂洗3次,用體積分?jǐn)?shù)為1%的甲苯胺藍(lán)乙醇液染色20 min,PBS清洗2次,無(wú)水乙醇漂洗,在空氣中干燥后用中性樹(shù)膠封片,于倒置熒光顯微鏡下觀察并拍照。
1.3.3ColⅡ免疫熒光染色鑒定軟骨細(xì)胞
細(xì)胞爬片的制備方法同上。取出已制備好的細(xì)胞爬片進(jìn)行免疫細(xì)胞熒光染色。具體步驟如下:用PBS-BSA[用PBS配制1%牛血清白蛋白(bovine serum albumine,BSA)]孵育細(xì)胞15 min,PBS漂洗2次,在4%多聚甲醛中固定細(xì)胞20 min;棄液體,PBS漂洗3次,用0.2%Triton-X-100通透細(xì)胞10 min;PBS漂洗3次,PBS-BSA孵育15 min;PBS漂洗2次,ColⅡ抗體4℃孵育過(guò)夜;次日,PBS漂洗3次,用PBS-BSA孵育15 min;PBS漂洗2次,加入山羊抗兔Dylight 488熒光二抗孵育1 h;PBS清洗3次后,用DAPI染色30 min;滴入防淬滅劑,封片,于倒置熒光顯微鏡下觀察并拍照。
1.3.4 實(shí)驗(yàn)分組
待第1代細(xì)胞貼壁長(zhǎng)滿至80%~90%時(shí),經(jīng)胰酶消化重懸后接種至6孔板,置于37℃、5%CO2培養(yǎng)箱中進(jìn)行常規(guī)培養(yǎng)。IL-1β按照說(shuō)明書(shū)用0.1%BSA溶解,TFs用PBS溶解稀釋成不同濃度,-20℃避光保存,備用。實(shí)驗(yàn)分為3個(gè)處理組:空白組(無(wú)干預(yù)無(wú)刺激,G0)、模型組(10 ng/mL IL-1β刺激,G1)和TFs干預(yù)組(G2)。待細(xì)胞長(zhǎng)滿至80%~90%時(shí),干預(yù)組在不同濃度的TFs中預(yù)處理2h后加入終質(zhì)量濃度為10ng/mL的IL-1β,模型組僅加入IL-1β和PBS,對(duì)照組加入PBS,各組細(xì)胞培養(yǎng)基總體積一致,培養(yǎng)24 h后,收集細(xì)胞進(jìn)一步分析。
1.3.5 細(xì)胞活性檢測(cè)
采用CCK-8試劑盒測(cè)定TFs對(duì)SD大鼠軟骨細(xì)胞是否有毒性作用[14]。第1代細(xì)胞經(jīng)胰酶消化后吹打均勻,以1×104個(gè)/孔細(xì)胞密度接種至96孔板中培養(yǎng)。待第2代軟骨細(xì)胞長(zhǎng)滿至80%~90%時(shí),分別加入0、25、50、75、100 μg/mL的TFs干預(yù)24 h,每組設(shè)置5個(gè)重復(fù)孔。更換新鮮完全培養(yǎng)基,每孔加入10 μL CCK-8溶液,輕輕振蕩混勻后常規(guī)培養(yǎng)2 h。用酶標(biāo)儀檢測(cè)在450 nm波長(zhǎng)處的光密度值,以無(wú)細(xì)胞孔作為空白組,無(wú)TFs干預(yù)孔作為對(duì)照組。定義對(duì)照組(TFs質(zhì)量濃度為0 μg/mL)細(xì)胞存活率為100%,其余各實(shí)驗(yàn)組細(xì)胞活性按下式計(jì)算,確定TFs對(duì)細(xì)胞的無(wú)毒性劑量。
1.3.6 熒光定量聚合酶鏈?zhǔn)椒磻?yīng)
用Trizol收取各組細(xì)胞,抽提軟骨細(xì)胞總RNA,并用NanoDrop蛋白核酸定量?jī)x檢測(cè)RNA濃度。取1 μg RNA,采用ReverTra Ace?反轉(zhuǎn)錄試劑盒制備cDNA模板,構(gòu)建熒光定量聚合酶鏈?zhǔn)椒磻?yīng)(quantitative real-time polymerase chain reaction,qRT-PCR)體系(10 μL)。反應(yīng)條件如下:95℃變性10 s,95℃退火5 s,60℃延伸
30 s,共40個(gè)循環(huán)。選用大鼠管家基因GAPDH為內(nèi)參,
將得到的各組CT值按公式2-ΔΔCT計(jì)算ColⅡ和蛋白聚糖(aggrecan,ACAN)的相對(duì)表達(dá)量。實(shí)驗(yàn)所用引物序列詳見(jiàn)表1。
1.3.7 統(tǒng)計(jì)分析
所有實(shí)驗(yàn)數(shù)據(jù)均以平均數(shù)±標(biāo)準(zhǔn)誤表示,統(tǒng)計(jì)分析采用Graphpad prism 5軟件的Student-t檢驗(yàn)處理,并采用雙尾t檢驗(yàn)進(jìn)行分析,以P<0.05表示差異有統(tǒng)計(jì)學(xué)意義。
表1 目的基因和內(nèi)參基因的引物序列Table 1Primer sequences of target and house-keeping genes used in this experiment
2.1 細(xì)胞形態(tài)觀察
在倒置相差顯微鏡下觀察可見(jiàn):分離培養(yǎng)的原代軟骨細(xì)胞接種約12h后開(kāi)始貼壁;4d左右細(xì)胞數(shù)目明顯增多,形態(tài)呈圓形或多角形;10d原代細(xì)胞融合成片,呈現(xiàn)典型“鋪路石”狀,可進(jìn)行傳代;傳代約6 h后的細(xì)胞開(kāi)始貼壁,生長(zhǎng)速度加快,4d左右即可傳代培養(yǎng),且細(xì)胞周圍可見(jiàn)具有折光性的細(xì)胞外基質(zhì)(圖2)。
圖2 在倒置相差顯微鏡下軟骨細(xì)胞形態(tài)觀察Fig.2Morphological observation of chondrocytes by inverted phase contrast microscope
2.2 細(xì)胞鑒定
軟骨細(xì)胞的特征性分泌產(chǎn)物酸性蛋白聚糖與甲苯胺藍(lán)堿性染液結(jié)合后呈異染性。在本實(shí)驗(yàn)中,甲苯胺藍(lán)染色顯示,培養(yǎng)細(xì)胞單層生長(zhǎng),呈多角形,細(xì)胞質(zhì)為藍(lán)紫色(圖3A)。Ⅱ型膠原(ColⅡ)免疫熒光染色顯示:細(xì)胞質(zhì)較疏松,呈綠色;細(xì)胞核較大,呈圓形或橢圓形,位于細(xì)胞中央,呈藍(lán)色(圖3B)。這表明培養(yǎng)的細(xì)胞為軟骨細(xì)胞。
圖3 在倒置熒光顯微鏡下軟骨細(xì)胞鑒定觀察Fig.3Identification of chondrocytes by inverted fluorescent microscope
2.3TFs對(duì)大鼠軟骨細(xì)胞活性的影響
待第2代大鼠軟骨細(xì)胞鋪滿至80%~90%時(shí),用0~100 μg/mL TFs干預(yù)細(xì)胞24 h,測(cè)定TFs對(duì)軟骨細(xì)胞活力的影響,篩選TFs的安全劑量閾值。結(jié)果(圖4)表明:與對(duì)照組(TFs質(zhì)量濃度為0 μg/mL)相比,25、50、75 μg/mL TFs干預(yù)組的細(xì)胞存活率間在統(tǒng)計(jì)學(xué)上無(wú)顯著差異(P>0.05);100 μg/mL TFs干預(yù)組的細(xì)胞存活率下降,且與對(duì)照組相比差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。表明0~75 μg/mL TFs是安全無(wú)毒的,不影響軟骨細(xì)胞活力。因此,后續(xù)研究選用25、50、75 μg/mL這3個(gè)劑量的TFs,以保證細(xì)胞處于良好的狀態(tài)。
圖4TFs對(duì)大鼠軟骨細(xì)胞活性的影響Fig.4Effect of TFs on cell viability of rat chondrocytes
2.4TFs對(duì)IL-1β誘導(dǎo)大鼠軟骨細(xì)胞合成因子活性的影響
提取軟骨細(xì)胞總RNA,通過(guò)qRT-PCR技術(shù)檢測(cè)TFs對(duì)炎癥軟骨細(xì)胞中合成因子活性的影響。如圖5所示:IL-1β處理細(xì)胞24 h后,ColⅡ和ACAN的表達(dá)量均極顯著降低(P<0.01);經(jīng)TFs(25、50、75 μg/mL)干預(yù)后,軟骨細(xì)胞中ColⅡ和ACAN mRNA表達(dá)量明顯高于模型組(P<0.05),并有效抑制了IL-1β引起的合成因子活性的降低,且隨著TFs濃度的增加,其抑制效果呈濃度依賴性變化。說(shuō)明TFs通過(guò)增強(qiáng)軟骨細(xì)胞合成因子ColⅡ和ACAN活性來(lái)抑制軟骨基質(zhì)降解。
圖5TFs對(duì)IL-1β誘導(dǎo)大鼠軟骨細(xì)胞合成因子活性的影響Fig.5Effects of TFs on anabolic activity of IL-1β-induced rat chondrocytes
2.5TFs對(duì)IL-1β誘導(dǎo)大鼠軟骨細(xì)胞分解因子活性的影響
MMP-13主要參與關(guān)節(jié)軟骨分解代謝,是目前在破壞軟骨基質(zhì)穩(wěn)態(tài)研究中受到關(guān)注較多的降解酶指標(biāo)[15]。本實(shí)驗(yàn)測(cè)定了茶黃素復(fù)合物對(duì)該因子mRNA表達(dá)量的影響。如圖6所示:與空白對(duì)照組相比,IL-1β處理大鼠軟骨細(xì)胞24 h后,MMP-13 mRNA表達(dá)量極顯著增加(P<0.001);與模型組相比,軟骨細(xì)胞預(yù)孵不同質(zhì)量濃度的TFs(25、50、75 μg/mL)2 h,再加入IL-1β(10 ng/mL)共培養(yǎng)24 h后,發(fā)現(xiàn)MMP-13的表達(dá)水平呈現(xiàn)出明顯的濃度依賴性降低(P<0.05)。由此可見(jiàn),TFs可減弱軟骨細(xì)胞分解因子MMP-13活性,抑制軟骨基質(zhì)的降解,維持軟骨基質(zhì)穩(wěn)態(tài)。
2.6TFs對(duì)IL-1β誘導(dǎo)大鼠軟骨細(xì)胞COX-2 mRNA表達(dá)的影響
圖6TFs對(duì)IL-1β誘導(dǎo)大鼠軟骨細(xì)胞分解因子活性的影響Fig.6Effect of TFs on catabolic activity of IL-1β-induced rat chondrocytes
OA在病變過(guò)程中會(huì)釋放出大量的炎癥因子,其中前列腺素E2(prostaglandin E2,PGE2)是參與該病變的主要介質(zhì),因此,其合成所需的關(guān)鍵酶環(huán)氧化酶(cyclooxygenase-2,COX-2)對(duì)于骨關(guān)節(jié)炎的發(fā)生和發(fā)展具有重要作用和影響[16]。在本研究中IL-1β處理大鼠軟骨細(xì)胞24 h后的COX-2 mRNA表達(dá)量呈極顯著增加(P<0.001);與模型組相比,軟骨細(xì)胞在不同質(zhì)量濃度的TFs(25、50、75 μg/mL)中預(yù)孵2 h再加入IL-1β(10 ng/mL)共培養(yǎng)24 h后,COX-2的表達(dá)水平明顯受到抑制(P<0.05),且抑制效果呈現(xiàn)濃度依賴性(圖7)。
圖7TFs對(duì)IL-1β誘導(dǎo)大鼠軟骨細(xì)胞環(huán)氧化酶(COX-2)蛋白表達(dá)的影響Fig.7Effect of TFs on cyclooxygenase-2(COX-2)expression of IL-1β-induced rat chondrocytes
2.7TFs對(duì)IL-1β誘導(dǎo)的大鼠軟骨細(xì)胞IL-1β mRNA表達(dá)的影響
如圖8所示:正常大鼠軟骨細(xì)胞經(jīng)IL-1β處理24 h后,炎癥因子IL-1β mRNA表達(dá)水平極顯著升高(P<0.01);在TFs(25、50、75 μg/mL)中預(yù)孵2h后再加入IL-1β共培養(yǎng)24 h,發(fā)現(xiàn)IL-1β表達(dá)水平呈濃度依賴性降低,且差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。
圖8TFs對(duì)IL-1β誘導(dǎo)大鼠軟骨細(xì)胞IL-1β mRNA表達(dá)的影響Fig.8Effect of TFs on IL-1β mRNA expression of IL-1β-induced rat chondrocytes
骨關(guān)節(jié)炎的發(fā)病率正在迅速增加,可能在今后幾十年內(nèi)成為世界上第四大致畸原因[17]。關(guān)節(jié)軟骨的破損與退化是OA的主要病理變化。關(guān)節(jié)軟骨由軟骨細(xì)胞及其分泌的細(xì)胞外基質(zhì)構(gòu)成,在成人的正常關(guān)節(jié)軟骨中,軟骨細(xì)胞僅占軟骨總體積的2%,其余為細(xì)胞外基質(zhì),主要由膠原(Ⅱ型膠原占80%~90%[18])和蛋白聚糖組成,其中,Ⅱ型膠原和蛋白聚糖是軟骨細(xì)胞的特異性分泌產(chǎn)物,常用于軟骨細(xì)胞鑒定。本實(shí)驗(yàn)培養(yǎng)的細(xì)胞經(jīng)甲苯胺藍(lán)染色呈異染性,Ⅱ型膠原免疫熒光染色呈陽(yáng)性,表明分離培養(yǎng)的細(xì)胞是軟骨細(xì)胞。
茶黃素是紅茶的有效活性成分之一,其分子結(jié)構(gòu)包含多個(gè)酚羥基及沒(méi)食子?;?,研究已證實(shí)其在肝、肺等人體器官炎癥中表現(xiàn)出豐富的抗炎活性[9-12]。CCK-8細(xì)胞增殖實(shí)驗(yàn)結(jié)果顯示,0~75 μg/mL的TFs是安全無(wú)毒的,不影響軟骨細(xì)胞活力。因此,本研究采用質(zhì)量濃度為25、50、75 μg/mL茶黃素來(lái)評(píng)估其對(duì)骨關(guān)節(jié)炎炎癥的調(diào)節(jié)功效及分子機(jī)制。
Ⅱ型膠原(ColⅡ)和蛋白聚糖(ACAN)是關(guān)節(jié)軟骨基質(zhì)的主要組成成分,其主要功能是調(diào)節(jié)細(xì)胞外基質(zhì)(ECM)的合成和分解,維持關(guān)節(jié)軟骨基質(zhì)穩(wěn)態(tài)。本研究發(fā)現(xiàn),大鼠軟骨細(xì)胞經(jīng)IL-1β誘導(dǎo)后,ColⅡ及ACAN含量明顯降低,與ZHAO等[19]的研究結(jié)果一致。此外還發(fā)現(xiàn),炎癥軟骨細(xì)胞經(jīng)TFs預(yù)干預(yù)后,其ColⅡ和ACAN mRNA的表達(dá)明顯上調(diào),改善了軟骨基質(zhì)合成受阻現(xiàn)象。MMP-13在骨關(guān)節(jié)炎關(guān)節(jié)軟骨退變中扮演了十分重要的角色,它可以通過(guò)降解關(guān)節(jié)軟骨基質(zhì)成分,破壞合成和分解代謝的動(dòng)態(tài)平衡。CHEN等[20]發(fā)現(xiàn),兔軟骨細(xì)胞經(jīng)IL-1β刺激24 h后,其MMP-13 mRNA的表達(dá)量極顯著增加,本實(shí)驗(yàn)研究結(jié)果與此相符。在此基礎(chǔ)上,添加TFs藥物預(yù)干擾能夠顯著降低MMP-13降解酶的蛋白表達(dá)量,可有效抑制軟骨基質(zhì)的降解現(xiàn)象。
大量研究表明,IL-1β可以調(diào)節(jié)軟骨細(xì)胞ECM的更新周轉(zhuǎn)率,引起ECM合成和分解代謝失衡[19-22]。同時(shí),處于基質(zhì)穩(wěn)態(tài)失衡環(huán)境下的軟骨細(xì)胞又將促進(jìn)包括其自身在內(nèi)的炎性因子及炎癥介質(zhì)(如COX-2 mRNA)的大量合成和釋放,進(jìn)而對(duì)炎癥反應(yīng)產(chǎn)生自行性推進(jìn)的影響,加大OA發(fā)展進(jìn)程。因此,控制軟骨細(xì)胞的炎癥反應(yīng)有利于控制或延緩OA進(jìn)展,并可能成為治療OA的關(guān)鍵。在本研究中,經(jīng)IL-1β誘導(dǎo)的軟骨細(xì)胞的IL-1β和COX-2 mRNA的表達(dá)量顯著增加,與陳文超等[23]報(bào)道的結(jié)果相符。本研究還發(fā)現(xiàn),TFs抑制IL-1β和COX-2 mRNA的表達(dá)呈濃度依賴性,其抗炎作用體現(xiàn)了多靶點(diǎn)性。以上結(jié)果表明,TFs對(duì)軟骨細(xì)胞炎癥因子IL-1β和炎癥介質(zhì)COX-2的表達(dá)具有抑制作用。
綜上所述,茶黃素作為紅茶的重要組成部分及營(yíng)養(yǎng)物質(zhì),可通過(guò)上調(diào)軟骨細(xì)胞合成因子ColⅡ和ACAN mRNA的表達(dá),并下調(diào)分解因子MMP-13 mRNA的表達(dá),來(lái)抑制IL-1β誘導(dǎo)的大鼠軟骨基質(zhì)的降解;同時(shí),通過(guò)降低炎癥因子IL-1β和炎癥誘導(dǎo)酶COX-2 mRNA的表達(dá)水平,抑制IL-1β誘導(dǎo)的大鼠軟骨細(xì)胞炎癥反應(yīng)。這些結(jié)果表明,TFs可以在一定程度上延緩大鼠軟骨細(xì)胞炎性退變,正向調(diào)控OA病理進(jìn)程。
[1]LEMETAYER J,TAYLOR S.Inflammatory joint disease in cats: Diagnostic approach and treatment.Journal of Feline Medicine and Surgery,2014,16(7):547-562.
[2]LOESER R F,GOLDRING S R,SCANZELLO C R,et al. Osteoarthritis:A disease of the joint as an organ.Arthritis and Rheumatism,2012,64(6):1697-1707.
[3]TROEBERG L,NAGASE H.Proteases involved in cartilage matrix degradation in osteoarthritis.Biochimica et Biophysica Acta,2012,1824(1):133-145.
[4]魏麗杰,王文雅.炎癥引起的軟骨細(xì)胞外基質(zhì)的變化對(duì)骨關(guān)節(jié)
炎病理進(jìn)展的作用.河北聯(lián)合大學(xué)學(xué)報(bào)(醫(yī)學(xué)版),2014,16(2): 170-171.
WEI L J,WANG W Y.Roles of changes of the extracellular matrix in cartilage caused by inflammation on osteoarthritis pathological progress.Journal of Hebei United University(Health Sciences),2014,16(2):170-171.(in Chinese)
[5]WANG D Y,QIAO J T,ZHAO X,et al.Thymoquinone inhibits IL-1β-induced inflammation in human osteoarthritis chondrocytes by suppressing NF-κB and MAPKs signaling pathway.Inflammation, 2015,38(6):2235-2241.
[6]WOJDASIEWICZ P,PONIATOWSKI L A,SZUKIEWICZ D.The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis.Mediators of Inflammation,2014(2): 561459.
[7]AKHTAR N,MILLRE M J,HAQQI T M.Effect of a herbal-leucine mix on the IL-1β-induced cartilage degradation and inflammatory gene expression in human chondrocytes.BMC Complementary and Alternative Medicine,2011,11:66.
[8]ZHANG H F,YAN J P,ZHUANG Y S,et al.Anti-inflammatory effects of farrerol on IL-1β-stimulated human osteoarthritis chondrocytes.European Journal of Pharmacology,2015,764:443-447.
[9]WEERAWATANAKORN M,LEE Y L,TSAI C Y,et al. Protective effect of theaflavin-enriched black tea extracts against dimethylnitrosamine-induced liver fibrosis in rats.Food and Function,2015,6(6):1832-1840.
[10]OKA Y,IWAI S,AMANO H,et al.Tea polyphenols inhibit rat osteoclastformationanddifferentiation.Journalof Pharmacological Sciences,2012,118(1):55-64.
[11]WU Y T,JIN F J,WANG Y L,et al.In vitro and in vivoanti-inflammatory effects of theaflavin-3,3'-digallate on lipopolysaccharide-induced inflammation.European Journal of Pharmacology,2017,794(5):52-60.
[12]KO H J,LO C Y,WANG B J,et al.Theaflavin-3,3'-digallate,a
black tea polyphenol,attenuates adipocyte-activated inflammatory response of macrophage associated with the switch of M1/M2-like phenotype.Journal of Functional Foods,2014,11:36-48.
[13]冷薇,馮文周.骨性關(guān)節(jié)炎(OA)臨床研究進(jìn)展及藥物治療.中國(guó)實(shí)用醫(yī)藥,2010,22(5):246-249. LENG W,FENG W Z.Clinical progress research and drug treatment of osteoarthritis(OA).China Practical Medicine,2010, 22(5):246-249.(in Chinese)
[14]ZHOU J,LU P,REN H,et al.17β-estradiol protects human eyelidderived adipose stem cells against cytotoxicity and increases transplanted cell survival in spinal cord injury.Journal of Cellular and Molecular Medicine,2014,18(2):326-343.
[15]WU X C,YIN Q S,ZHENG C H,et al.Alendronate impact on ColⅡ, MMP-13,and β-catenin in osteoarthritis rats.International Journal of Clinical and Experimental Pathology,2016,9(3):3618-3623.
[16]HUANG C Y,HUANG L F,LIANG C C T,et al.COX-2 and iNOS are critical in advanced glycation end product-activated chondrocytes in vitro.European Journal of Clinical Investigation, 2009,39(5):417-428.
[17]URQUHART D M,SOUFAN C,TEICHTAHL A J,et al.Factors that may mediate the relationship between physical activity and the risk for developing knee osteoarthritis.Arthristis Research& Therapy,2008,10:203.
[18]SHINOMURAL T,ITO K,H??K M,et al.A newly identified enhancer element responsible for typeⅡcollagen gene expression. The Journal of Biochemistry,2012,152(6):565-575.
[19]ZHAO H H,ZHANG T E,XIA C,et al.Berberine ameliorates cartilage degeneration in interleukin-1β-stimulated rat chondrocytes and in a rat model of osteoarthritis via Akt signaling.Journal of Cellular and Molecular Medicine,2014,18(2):283-292.
[20]CHEN W P,XIONG Y,HU P F,et al.Baicalein inhibits MMPs expression via a MAPK-dependment mechanism in chondrocytes. Cellular physiology and Biochemistry,2015,36(1):325-333.
[21]HUANG H J,LIU Q,LIU L,et al.Effect of epigallocatechin-3-gallate on proliferation and phenotype maintenance in rabbit articular chondrocytes in vitro.Experimental and Therapeutic Medicine,2015,9(1):213-218.
[22]NISHITANI K,ITO H,HIRAMITSU T,et al.PGE2 inhibits MMP expression by suppressing MKK4-JNK MAP kinase-c-JUN pathway via EP4 in human articular chondrocytes.Journal of Cellular Biochemistry,2010,109(2):425-433.
[23]陳文超,周然,王永輝,等.骨靈膏及其拆方對(duì)骨關(guān)節(jié)炎模型大鼠炎性細(xì)胞因子與聚蛋白多糖酶的影響.中醫(yī)雜志,2016,57 (3):245-249. CHEN W C,ZHOU R,WANG Y H,et al.Effect of Gulinggao and its disassembled prescriptions on inflammatory cytokines and aggrecanase of osteoarthritis model rats.Journal of Traditional Chinese Medicine,2016,57(3):245-249.(in Chinese with English abstract)
Effect of theaflavins on inflammatory degeneration of rat chondrocytes induced by interleukin-1β.
Journal of Zhejiang University(Agric.&Life Sci.),2017,43(4):511-518
ZHOU Ying1?,HUANG Qian2?,WANG Shuai2,CHEN Ping1*(1.Department of Tea Science,College of Agriculture and Biotechnology,Zhejiang University,Hangzhou 310058,China;2.School of Basic Medical Sciences,Zhejiang University, Hangzhou 310058,China)
theaflavins;osteoarthritis;chondrocyte;interleukin-1β;cyclooxygenase-2;inflammatory degeneration
S 571.1;R 684.3;R 392.12
A
10.3785/j.issn.1008-9209.2016.12.282
國(guó)家茶葉產(chǎn)業(yè)技術(shù)體系項(xiàng)目(CARS-23)。
*通信作者(Corresponding author):陳萍(http://orcid.org/0000-0001-7995-6168),E-mail:pingchen@zju.edu.cn
周盈(http://orcid.org/0000-0002-4231-3270),E-mail:vaelailai@foxmail.com。?共同
第一作者
2016-12-28;接受日期(Accepted):2017-02-16